MannKind Corp (MNKD)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.33B
Last updated: Nov 17, 2026 at 11:06 AM ET
MannKind Corp (MNKD) Stock Forecast
Analysts expect MannKind (MNKD) to earn $0.02 per share in the fiscal year ending Dec 31, 2026, on revenue of $434.56M. Of 9 analysts, 8 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 9 ratings average 2.11, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 89% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 8 | 88.9% |
| Hold | 1 | 11.1% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 9
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 700.0% and revenue estimates rise 19.5%.
- Fiscal year ending Dec 31, 2026
- $0.02
- EPS consensus, revenue $434.56M
- Fiscal year ending Dec 31, 2027
- $0.16
- EPS consensus, revenue $519.47M
- Next report
- Feb 24, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.02 | $0.01 to $0.02 | 4 | $434.56M | $429.29M to $442.95M | 7 |
| Dec 31, 2027 | $0.16 | $0.05 to $0.21 | 4 | $519.47M | $470.87M to $571.60M | 9 |
Quarterly Estimates
The EPS consensus falls from $0.00 for the quarter ending Dec 31, 2026 to -$0.02 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.00 | -$0.06 to $0.04 | 11 | $135.55M | $123.33M to $148.79M | 11 |
| Mar 31, 2027 | -$0.02 | -$0.02 to -$0.02 | 1 | $128.60M | $128.60M to $128.60M | 1 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 1 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 1 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 33.3% from $0.03.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $0.02 | $0.03 | $0.03 | $0.03 | $0.03 | -50.0% |
| Fiscal year ending Dec 31, 2027 | $0.16 | $0.14 | $0.13 | $0.13 | $0.13 | +23.5% |
| Quarter ending Mar 31, 2027 | -$0.02 | $0.01 | -$0.02 | -$0.02 | -$0.02 | N/A |
Frequently Asked Questions About MNKD
What is the MNKD stock forecast?
Consensus analyst estimates put MannKind's EPS at $0.02 for the fiscal year ending Dec 31, 2026, on revenue of $434.56M. The consensus rating from 9 analysts is Buy.
How do analysts rate MNKD stock?
Of 9 analysts covering MannKind, 0 rate it Strong Buy, 8 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from MNKD next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.02, with estimates from $0.01 to $0.02 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.16, with estimates from $0.05 to $0.21 from 4 analysts.
What revenue do analysts expect from MannKind next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $434.56M, with estimates from $429.29M to $442.95M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $519.47M, with estimates from $470.87M to $571.60M.
How many analysts cover MNKD?
9 analysts rate MannKind stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
MNKD pages: Overview, Earnings, Forecast, Financials, Competitors